Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types | Zendy

Shiro Takamatsu | Zendy; J. Brown | Zendy; Ken Yamaguchi | Zendy; Junzo Hamanishi | Zendy; Koji Yamanoi | Zendy; Hisamitsu Takaya | Zendy; Tomoko Kaneyasu | Zendy; Seiichi Mori | Zendy; Masaki Mandai | Zendy; Noriomi Matsumura | Zendy

AI Assistant Blog Pricing

Home ZAIA Blog

Open Access

Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types

Author(s) -

Shiro Takamatsu,

J. Brown,

Ken Yamaguchi,

Junzo Hamanishi,

Koji Yamanoi,

Hisamitsu Takaya,

Tomoko Kaneyasu,

Seiichi Mori,

Masaki Mandai,

Noriomi Matsumura

Publication year - 2021

Publication title -

jco precision oncology

Language(s) - English

Resource type - Journals

ISSN - 2473-4284

DOI - 10.1200/po.21.00141

Subject(s) - homologous recombination , recombination , genetics , cancer , homologous chromosome , biology , computational biology , dna , gene

EXPRESSION OF CONCERN The Original Report by Takamatsu et al entitled, “Utility of Homologous Recombination Deficiency Biomarkers Across Cancer Types,” ( JCO Prec Onc 10.1200/PO.21.00141) published in JCO Precision Oncology on August 11, 2021, is under further review. Until the authors and their institutions can fully provide additional information, readers should interpret the findings presented with caution. An update will be provided when our investigation is complete.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research